Defining Fingerprint Pattern of Cardiotoxicity and Targeting Specific Underlying Mechanisms of Cardiotoxicity Could be the Way for Successful Cardioprotective Measures in Paediatric Cancer Patients Treated with Anthracyclines - Cancer Research & Clinical Imaging

Anthracycline  Chemotherapy  are  administered  to  more  than 50%  of  children  with  cancer  and  up  to  60%  of  those  treated  with  an anthracycline will develop echocardiographic abnormalities [1]. Compared to their siblings, childhood cancer survivors (CCSs) have a 15-fold increased risk of developing congestive heart failure (CHF) and  mortality  rate  in  those  with  CHF  approaches  50%  [2].  Once  anthracycline-induced  cardiomyopathy  develops,  it  is  commonly progressive, with no definitive treatment other than implantation of a left ventricular assist device and/or heart transplantation [3,4].

Read more...PDF in Iris Publishers